Skip to content

Biotech Investments

Wedbush’s Head Of Healthcare Equity Research Is Bullish On These Genetic-Medicine And Oncology Stocks

Dr. David Nierengarten, Managing Director and Head of Healthcare Equity Research at Wedbush Securities, sees potential in many biotech stocks, especially in the genetic-medicine and oncology spaces. For several specific genetic-medicine and oncology names that Nierengarten is particularly bullish on – including one company with a gene therapy for a rare retinal disease that causes significant vision loss (and sometimes… 

CLICK HERE »Wedbush’s Head Of Healthcare Equity Research Is Bullish On These Genetic-Medicine And Oncology Stocks

Which Of These Small-Cap Biotechs With Unique COVID-19 Vaccine Candidates Is The Better Buy?

At the beginning of the year, the two biotechs highlighted in today’s article weren’t even big enough to be considered microcap stocks. Now, thanks to their respective COVID-19 vaccine programs, both are fast-growing small-cap stocks with “intriguing twists with their respective COVID-19 vaccine candidates.” So which of these two coronavirus stocks might be the better buy? CLICK HERE.

3 Biotech Penny Stocks To Watch Right Now – Including One That’s Been Having An Epic Year

Today’s article highlights three biotech penny stocks to watch right now, including one that the author notes has “had an epic year so far”: It started the year trading under $1 and proceeded to go as high as $5.55 before recently being driven down to as low as $1.68 – and may now be experiencing a turnaround! For more on… 

CLICK HERE »3 Biotech Penny Stocks To Watch Right Now – Including One That’s Been Having An Epic Year

Biotech Divergence?

When it comes to the S&P 500 and one of the ETFs that represents the overall biotech sector (the iShares Nasdaq Biotechnology ETF), the author of today’s article observes that “the paths of these two investments appear to be diverging.” Given this apparent divergence, he questions whether, despite all the recent medical news, biotech stocks have already had their run.… 

CLICK HERE »Biotech Divergence?

Analysts Are Bullish On These 2 Biotech Stocks

“2020 will be remembered as the year of the biotech sector,” declares the author of today’s article, who proceeds to highlight two biotech stocks that Morgan Stanley is bullish on – and which have also earned “Strong Buy” consensus ratings from the analyst community at large. For these two biotech stocks with significant upside potential, CLICK HERE.

Bad News For Its Competitor Could Be Great News For This Small-Cap Biotech – And Its Shareholders

In January, the small-cap biotech highlighted in today’s article received FDA approval for its treatment for childhood peanut allergy – and with peanut allergy being the most common food allergy in the U.S. (with cases of the condition rising rapidly) and the fact that this is currently the only FDA-approved treatment for the condition (thanks to a competitor encountering some… 

CLICK HERE »Bad News For Its Competitor Could Be Great News For This Small-Cap Biotech – And Its Shareholders

ETFs: A Remedy For Biotech Risks

The solution to the substantial risks associated with biotech stocks (especially small biotech firms)? Biotech ETFs! Today’s article highlights six biotech ETFs to consider buying, noting that “Some provide well-rounded access to the space, while others acutely focus on certain aspects of the space, such as cancer treatments or drugs to battle infectious diseases.” For these six biotech ETFs, CLICK… 

CLICK HERE »ETFs: A Remedy For Biotech Risks

This Little-Known Biotech’s Blood Plasma-Based Coronavirus Therapy Could Soon Bring It A Lot Of Attention

Of all the companies working on the development of potential COVID-19 vaccines and therapeutics, the one highlighted in today’s article – a small Israel-based biotech that specializes in blood plasma-based treatments – is one of the least well-known. However, given that plasma-based therapies have already been shown to be effective in treating severe cases of COVID-19, this company could start… 

CLICK HERE »This Little-Known Biotech’s Blood Plasma-Based Coronavirus Therapy Could Soon Bring It A Lot Of Attention

“Already Lucrative And Growing Like Gangbusters”: The Little-Known Biotech Segment Set For A Massive Breakout

“As an investor, this sets up a great opportunity to get in on the ground floor and earn triple-digit profits in short order,” advises the author of today’s article in regards to a little-known segment of the thriving biotech industry that appears poised for a massive breakout to the upside in the coming months. Just what is this biotech segment… 

CLICK HERE »“Already Lucrative And Growing Like Gangbusters”: The Little-Known Biotech Segment Set For A Massive Breakout